{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:57:15Z","timestamp":1791161835891,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T00:00:00Z","timestamp":1398556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Botulinum toxins are considered first-line therapy for treatment of cervical dystonia (CD) and must be injected on a repeat basis. Understanding the duration of clinical benefit of botulinum toxins and its impact on health care utilization are thus important in the contemporary environment. However, there is currently no overall consensus on the duration of effect of onabotulinumtoxinA in the treatment of CD. We performed a systematic review and meta-analysis to identify the duration of effect of onabotulinumtoxinA in CD and investigate factors that may influence it.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic literature search identified prospective or retrospective studies reporting duration of effect of onabotulinumtoxinA for the treatment of CD. Inclusion criteria included peer-reviewed, non-review, English-language articles published between January 1980 and January 2013. A formal meta-analysis using Comprehensive Meta-Analysis Version 2 was conducted to identify the duration of effect of onabotulinumtoxinA in the treatment of CD; both fixed and random effects models were performed. Subgroup analyses were performed to identify factors that influenced the duration of effect of onabotulinumtoxinA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 18 studies (including &gt;1,900 patients) met the inclusion criteria and were used for the meta-analysis. The mean duration of effect of onabotulinumtoxinA in CD was found to be 93.2\u00a0days (95% CI 91.8-94.6\u00a0days) for the fixed effects model and 95.2\u00a0days (95% CI 88.9-101.4\u00a0days) for the random effects model. A meta-regression found that dose of onabotulinumtoxinA and country of origin influenced the duration of effect of onabotulinumtoxinA, whereas quality score of the article and study type did not. In particular, doses \u2265180 Units were associated with longer durations of effect than doses &lt;180 Units (107-109 days vs. 86-88 days, respectively; p\u2009&lt;\u20090.01). Limitations included pooling studies that used discrete definitions of duration and had different designs and study quality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Based on the published literature, the mean duration of effect of onabotulinumtoxinA in CD was 93-95 days (13.2-13.5\u00a0weeks). This suggests that, in general, patients with CD treated with onabotulinumtoxinA should require ~4 treatments per year.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-14-91","type":"journal-article","created":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T01:02:30Z","timestamp":1398560550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia"],"prefix":"10.1186","volume":"14","author":[{"given":"Wallace A","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre M","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,27]]},"reference":[{"issue":"7","key":"1009_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","volume":"13","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Tsui J, Bergeron C: Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007, 13 (7): 411-416. 10.1016\/j.parkreldis.2007.02.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"1009_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K: Response and immunoresistance to botulinum toxin injections. Neurology. 1995, 45 (9): 1743-1746. 10.1212\/WNL.45.9.1743.","journal-title":"Neurology"},{"issue":"1","key":"1009_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF02850184","volume":"22","author":"A Brashear","year":"2005","unstructured":"Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J: Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther. 2005, 22 (1): 49-55. 10.1007\/BF02850184.","journal-title":"Adv Ther"},{"key":"1009_CR4","unstructured":"BOTOX\u00ae [package insert]. 2013, Irvine, CA: Allergan, Inc."},{"issue":"12","key":"1009_CR5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1007\/s00415-012-6510-x","volume":"259","author":"E Zoons","year":"2012","unstructured":"Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA: Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol. 2012, 259 (12): 2519-2526. 10.1007\/s00415-012-6510-x.","journal-title":"J Neurol"},{"issue":"3","key":"1009_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1185\/030079905X36396","volume":"21","author":"K Bihari","year":"2005","unstructured":"Bihari K: Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin. 2005, 21 (3): 433-438. 10.1185\/030079905X36396.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1009_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K: A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009, 31 (5): 463-466. 10.1179\/174313209X405137.","journal-title":"Neurol Res"},{"issue":"1","key":"1009_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/PL00007848","volume":"249","author":"M Naumann","year":"2002","unstructured":"Naumann M, Yakovleff A, Durif F: A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002, 249 (1): 57-63. 10.1007\/PL00007848.","journal-title":"J Neurol"},{"issue":"5","key":"1009_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/WNF.0b013e31826538c7","volume":"35","author":"D Charles","year":"2012","unstructured":"Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF: Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012, 35 (5): 208-214. 10.1097\/WNF.0b013e31826538c7.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1009_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/jama.1994.03520020027007","volume":"272","author":"MK Cho","year":"1994","unstructured":"Cho MK, Bero LA: Instruments for assessing the quality of drug studies published in the medical literature. JAMA. 1994, 272 (2): 101-104. 10.1001\/jama.1994.03520020027007.","journal-title":"JAMA"},{"issue":"14","key":"1009_CR11","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1212\/WNL.0b013e31826d5ec0","volume":"79","author":"JM Pellock","year":"2012","unstructured":"Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D\u2019Cruz O: Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012, 79 (14): 1482-1489. 10.1212\/WNL.0b013e31826d5ec0.","journal-title":"Neurology"},{"issue":"4","key":"1009_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jclinepi.2011.08.006","volume":"65","author":"M Crowe","year":"2012","unstructured":"Crowe M, Sheppard L, Campbell A: Reliability analysis for a proposed critical appraisal tool demonstrated value for diverse research designs. J Clin Epidemiol. 2012, 65 (4): 375-383. 10.1016\/j.jclinepi.2011.08.006.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"1009_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jclinepi.2010.08.006","volume":"64","author":"TA Shamliyan","year":"2011","unstructured":"Shamliyan TA, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, Janes G, Maglione M, Moher D, Nasser M, Robinson KA, Segal JB, Tsouros S: Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011, 64 (6): 637-657. 10.1016\/j.jclinepi.2010.08.006.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1009_CR14","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/pon.1754","volume":"20","author":"HR Han","year":"2011","unstructured":"Han HR, Kim J, Lee JE, Hedlin HK, Song H, Song Y, Kim MT: Interventions that increase use of Pap tests among ethnic minority women: a meta-analysis. Psycho-Oncology. 2011, 20 (4): 341-351. 10.1002\/pon.1754.","journal-title":"Psycho-Oncology"},{"issue":"2","key":"1009_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000120024","volume":"30","author":"C Xiong","year":"2008","unstructured":"Xiong C, Tang Y, van Belle G, Miller JP, Launer LJ, Morris JC: Evaluating the quality of longitudinal statistical applications in original publications on Alzheimer\u2019s disease. Neuroepidemiology. 2008, 30 (2): 112-119. 10.1159\/000120024.","journal-title":"Neuroepidemiology"},{"issue":"4","key":"1009_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1017\/S1041610205001663","volume":"17","author":"B Draper","year":"2005","unstructured":"Draper B, Low LF: What is the effectiveness of acute hospital treatment of older people with mental disorders?. Int Psychogeriatr. 2005, 17 (4): 539-555. 10.1017\/S1041610205001663.","journal-title":"Int Psychogeriatr"},{"issue":"11","key":"1009_CR17","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","volume":"64","author":"R Benecke","year":"2005","unstructured":"Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S: A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005, 64 (11): 1949-1951. 10.1212\/01.WNL.0000163767.99354.C3.","journal-title":"Neurology"},{"issue":"1","key":"1009_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1590\/S0004-282X2008000100005","volume":"66","author":"CH Camargo","year":"2008","unstructured":"Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC: Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr. 2008, 66 (1): 15-21. 10.1590\/S0004-282X2008000100005.","journal-title":"Arq Neuropsiquiatr"},{"issue":"7","key":"1009_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003, 60 (7): 1186-1188. 10.1212\/01.WNL.0000055087.96356.BB.","journal-title":"Neurology"},{"issue":"1","key":"1009_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2009.06.004","volume":"16","author":"FM Maia","year":"2010","unstructured":"Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER: Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord. 2010, 16 (1): 8-11. 10.1016\/j.parkreldis.2009.06.004.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1009_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J: Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005, 20 (5): 592-597. 10.1002\/mds.20376.","journal-title":"Mov Disord"},{"issue":"1","key":"1009_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H: A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998, 64 (1): 6-12. 10.1136\/jnnp.64.1.6.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1009_CR23","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M: Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002, 72 (4): 459-462.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1009_CR24","first-page":"115","volume":"17","author":"K Brockmann","year":"2012","unstructured":"Brockmann K, Schweitzer K, Beck G, Wachter T: Comparison of different preparations of botulinumtoxin A in the treatment of cervical dystonia. Neurol Asia. 2012, 17: 115-119.","journal-title":"Neurol Asia"},{"issue":"12","key":"1009_CR25","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/S0149-2918(00)83049-0","volume":"22","author":"A Brashear","year":"2000","unstructured":"Brashear A, Watts MW, Marchetti A, Magar R, Lau H, Wang L: Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther. 2000, 22 (12): 1516-1524. 10.1016\/S0149-2918(00)83049-0.","journal-title":"Clin Ther"},{"issue":"2","key":"1009_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1212\/WNL.40.2.277","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K: Botulinum toxin injections for cervical dystonia. Neurology. 1990, 40 (2): 277-280. 10.1212\/WNL.40.2.277.","journal-title":"Neurology"},{"issue":"1","key":"1009_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/mds.870130130","volume":"13","author":"A Brashear","year":"1998","unstructured":"Brashear A, Ambrosius WT, Eckert GJ, Siemers ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord. 1998, 13 (1): 158-161. 10.1002\/mds.870130130.","journal-title":"Mov Disord"},{"issue":"3","key":"1009_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00002826-199106000-00011","volume":"14","author":"RM Dubinsky","year":"1991","unstructured":"Dubinsky RM, Gray CS, Vetere-Overfield B, Koller WC: Electromyographic guidance of botulinum toxin treatment in cervical dystonia. Clin Neuropharmacol. 1991, 14 (3): 262-267. 10.1097\/00002826-199106000-00011.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"1009_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M: Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008, 23 (10): 1353-1360. 10.1002\/mds.22157.","journal-title":"Mov Disord"},{"issue":"1","key":"1009_CR30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNF.0b013e3181c46f48","volume":"33","author":"EM Quagliato","year":"2010","unstructured":"Quagliato EM, Carelli EF, Viana MA: A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clin Neuropharmacol. 2010, 33 (1): 22-26.","journal-title":"Clin Neuropharmacol"},{"key":"1009_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","volume":"67","author":"M Hallett","year":"2013","unstructured":"Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J: Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013, 67: 94-114.","journal-title":"Toxicon"},{"issue":"1\u20132","key":"1009_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S: Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011, 308 (1\u20132): 103-109.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1009_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, for the German Dystonia Study Group: What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry. 1998, 64 (1): 13-17. 10.1136\/jnnp.64.1.13.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1009_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00702-012-0872-1","volume":"120","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P: AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm. 2013, 120 (2): 299-307. 10.1007\/s00702-012-0872-1.","journal-title":"J Neural Transm"},{"issue":"1","key":"1009_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X","volume":"15","author":"A Brashear","year":"2000","unstructured":"Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W: Patients\u2019 perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord. 2000, 15 (1): 150-153. 10.1002\/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X.","journal-title":"Mov Disord"},{"issue":"8","key":"1009_CR36","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","volume":"53","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K, Donovan DT: Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990, 53 (8): 633-639. 10.1136\/jnnp.53.8.633.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1009_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W: Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005, 65 (9): 1423-1429. 10.1212\/01.wnl.0000183055.81056.5c.","journal-title":"Neurology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-14-91\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:45:29Z","timestamp":1630554329000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-14-91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-14-91","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,27]]},"assertion":[{"value":"18 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"91"}}